IZO:CC - Izotropic Completes Izoview Development and Assembly Prepares for Final Testing
(TheNewswire)
VANCOUVER, BC – TheNewswire – December 1 ,2022 – Izotropic Corporation (“ Izotropic ” orthe “ Company ”) (CSE: IZO ) (OTC: IZOZF )(FSE: 1R3 ), a medical device company commercializing IzoView, adedicated breast CT (computed tomography) imaging platform, for themore accurate detection and diagnosis of breast cancers is pleased toannounce that it has completed the final engineering ofIzoView.
IzoView is now fully assembled and being prepared forfinal software testing and certifications of the pre-commercial modelto be used in the Company’s clinical study in the U.S. for marketauthorization. IzoView’s hardware components are production ready,and the Company will select a third-party manufacturer in the U.S. forcommercial production and assembly, while the clinical study isunderway.
The IzoView commercial model has been designed andengineered in a modular subsystem format, meaning each subsystem canbe manufactured, packaged, and shipped easily, and the componentdesign makes installation and maintenance fast and efficient. IzoViewis now producing full-motion 360-degree images, and with 360-degreedata, Izotropic engineers will finalize and refine the overallsoftware integration of the subsystems as a complete unit. Engineerswill also prepare for a series of standard commissioning andregulatory tests while taking hundreds of images for reconstructionpurposes using custom 3D-printed phantoms that are representative ofpatient's breasts.
The 360-degree phantom imaging data will be integratedinto IzoView’s machine learning algorithm image reconstructionsoftware developed by Izotropic’s partner, The Johns Hopkins University School ofMedicine . This work will bepresented at the SPIE Physics of Medical Imaging Conference on February 21, 2023 .
The Company will use these 3D phantom images toshowcase IzoView’s capabilities to the medical community and toprovide unique and interesting visual content for social mediaawareness initiatives in the investment community.
A professional videographer is scheduled to producevideo of IzoView and interviews with Izotropic’s engineers,advisors, and founders at the Sacramento facility in earlyDecember. This content and IzoView's phantom images will be availableacross the Company's social media channels and website and integratedinto corporate materials when completed.
The Company is on track for unveiling IzoView,disclosing milestones with projected timelines, providing an overviewof the financial model, and presenting new corporate materials, socialmedia, and marketing plans by the end of 2022.
ON BEHALF OF THE BOARD
Dr. John McGraw
Investor Relations Contact:
James Berard
Email: info@izocorp.com
Toll Free: 1-833-IZOCORP ext.1
Media Inquiries Contact:
Jaclyn Thast
Email: jaclyn@izocorp.com
Toll Free: 1-833-IZOCORP ext.3
About Izotropic Corporation
Izotropic Corporation is the only publicly tradedcompany commercializing a dedicated breast CT imaging platform,IzoView, for the more accurate detection and diagnosis of breastcancers. To expedite patient and provider access to IzoView,Izotropic's initial clinical study intends to demonstrate superiorperformance of diagnostic breast CT imaging over diagnosticmammography procedures. In follow-on clinical studies, Izotropicintends to validate platform applications, including breast screeningin radiology, treatment planning and monitoring in surgical oncology,and breast reconstruction and implant monitoring in plastic andreconstructive surgery.
More information about Izotropic Corporation can befound on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com.
Forward-Looking Statements
This document may contain statements that are"Forward-Looking Statements," which are based upon thecurrent estimates, assumptions, projections, and expectations of theCompany's management, business, and its knowledge of the relevantmarket and economic environment in which it operates. The Company hastried, where possible,
to identify such information and statements by usingwords such as "anticipate," "believe,""envision," "estimate," "expect,""intend," "may," "plan,""predict," "project," "target,""potential," "will," "would,""could," "should," "continue,""contemplate" and other similar expressions and derivationsthereof in connection with any discussion of
future events, trends or prospects or future operatingor financial performance, although not all forward-looking statementscontain these identifying words.
These statements are not guarantees of performance andinvolve risks including those related to capital requirements, anduncertainties that are difficult to control or predict, and as such,they may cause future results of the Company's activity to differsignificantly from the content and implications of such statements.Forward-Looking Statements are pertinent only as of the date on whichthey are made, and the Company undertakes no obligation to update orrevise any Forward-Looking Statements to reflect new information orthe occurrence of future events or circumstances unless otherwiserequired to do so by law. Neither the Company nor its shareholders,officers, and consultants shall be liable for any action and theresults of any action taken by any person based on the informationcontained herein, including, without limitation the purchase or saleof Company securities. Nothing in this document should be deemed to bemedical or other advice of any kind. All images are for illustrativepurposes only. IzoView is not yet approved for sale.
Copyright (c) 2022 TheNewswire - All rights reserved.